Anti-tumor effects of OK432 optimized umbilical vein endothelial cell vaccine in murine breast cancer
10.3969/j.issn.1001-1978.2014.10.020
- VernacularTitle:OK432优化的内皮细胞疫苗抗小鼠乳腺癌作用研究
- Author:
Maolei XU
;
Ling ZHOU
;
Xiaoping YANG
- Publication Type:Journal Article
- Keywords:
umbilical vein endothelial cell vaccine;
anti-angiogenesis therapy;
OK432;
cancer immuno-therapy;
EAC breast cancer;
ICR mice
- From:
Chinese Pharmacological Bulletin
2014;(10):1425-1429,1430
- CountryChina
- Language:Chinese
-
Abstract:
Aim To investigate the anti-EAC breast cancer effects of viable human umbilical vein endothe-lial cells ( HUVECs) vaccine. Methods Subconflu-ent HUVECs were mixed with OK432 to prepare HU-VECs-OK432 vaccine, and the anti-tumor efficacy of HUVECs-OK432 was investigated using a subcutaneous tumor model of EAC breast cancer. ELISA, splenic lymphocyte proliferation assay and cytotoxic T lympho-cytes ( CTL ) killing assay were adopted to detect the humoral and cellular immune responses after HUVECs-OK432 immunization. Results HUVECs-OK432 im-munization significantly inhibited the growth of EAC tumor in mice in the prophylactic procedures. High ti-ter of anti-HUVEC antibody was elicited by HUVECs-OK432 immunization. The proliferation activity of splenocytes from mice immunized with HUVECs-OK432 was significantly increased. T lymphocytes iso-lated from HUVECs-OK432-immunized mice were dose dependently killing HUVECs in vitro. Conclusion Strong humoral and cellular immune responses targeting HUVEC are elicited by HUVECs-OK432 immuniza-tion, which results in a significant inhibition on the growth of EAC tumor in mice.
